IL-15   

GtoPdb Ligand ID: 4981

Synonyms: interleukin-15
Comment: IL-15 and IL-2 are cytokines that share common biological effects, but also exhibit distinct, and sometimes competing, functions [7].
Nektar Therapeutics is developing a long-acting polymer-engineered (e.g. PEGylated) IL-15 conjugate, code named NKTR-255 (structure not disclosed), as a potential immuno-oncology agent- see their patent US20170035898 [4]. The conjugate has been optimised for binding to the IL-15Rα subunit and improved plasma and tumour exposure compared to native IL-15. This agent is in preclinical evaluation (August 2017).
Calypso Biotech have an anti-IL-15 monoclonal antibody named CALY-002 in their development pipeline. CALY-002 has potential for the treatment of refractory celiac disease and other inflammatory conditions at mucosal interfaces within the gastro-intestinal tract (e.g. eosinophilic esophagitis) [6]. The EMA granted CALY-002 orphan drug designation for the treatment of eosinophilic esophagitis in 2016 [2].
Species: Human
Natural/Endogenous Targets
Target
Interleukin-15 receptor
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Interleukin-15 receptor subunit α Hs Agonist Agonist 11.4 pKd - 4
pKd 11.4 (Kd 3.8x10-12 M) [4]
Description: Binding of recombinant hIL-15 to IL-15Rα subunit using Surface Plasmon Resonance (SPR)
Interleukin-15 receptor Hs Agonist Agonist 11.4 pIC50 - 8
pIC50 11.4 (IC50 3.8x10-12 M) [8]
Description: Binding of rhIL-15 in vitro, using cells expressing the intact hIL-15Rα-hIL-15Rβ-hγ complex.
Other ligands which bind to or alter the activity of this ligand
Key to terms and symbols Click column headers to sort
Ligand Sp. Type Action Value Parameter Concentration range (M) Reference
compound 76 [PMID: 28657314] Hs Antagonist Antagonist 4.7 pKd - 5
pKd 4.7 (Kd 2.18x10-5 M) [5]
Description: By SPR binding to the IL-15 superagonist RLI.